


Trends in median annual price for disease-modifying therapies for multiple sclerosis by category; 1997 to 2020



Drug	5 Year Change*	1 Year Change**	Annual Cost 2020
Interferons			
Betaseron	48.9%	4.6%	\$103,302
Avonex	48.0%	2.0%	\$91,835
Rebif	46.7%	4.8%	\$103,647
Extavia	39.0%	0.0%	\$81,079
Plegridy	48.0%	2.0%	\$91,835
Glatiramer Acetate			
Copaxone 20	16.4%	0.0%	\$86,554
Copaxone 40	16.5%	0.0%	\$75,816
Glatopa 20		-71.1%	\$18,250
Glatopa 40		-70.2%	\$19,500
Glat Acet 20		0.0%	\$23,725
Glat Acet 40		0.0%	\$25,350
Oral DMTs			
Gilenya	58.2%	5.5%	\$105,390
Aubagio	40.9%	5.0%	\$93,296
Tecfidera	59.9%	6.0%	\$100,690
Mayzent			\$93,367
Mavenclad			\$107,460
Vumerity			\$88,000
Infusions			
Tysabri	38.1%	7.1%	\$89,074
Lemtrada	22.0%	5.2%	\$80,320
Ocrevus		0.0%	\$65,000

Notes:
 Annual price estimated from wholesale acquisition costs (First Databank)
 Dashed line is projected annual price of Betaseron assuming only inflationary increases in price (medical care)
 *The annual price for Lemtrada is based on four 12 mg vials (Package insert dosing: 12 mg/day (5 vials) for five consecutive days in first year; 12 mg/day (3 vials) for three days in year 2)
 **2015 to 2020 (Feb); **2019 to 2020 (Feb)
 Updated 2.20.2020

Hartung, DM- PharmD, MPH; Oregon State University/Oregon Health and Science University


The National MS Society

modifying therapies (DMTs). 77% of respondents reported taking one of the following six medications:

DMT	Annual Cost	5 Year Change	DMT	Annual Cost	5 Year Change
Ocrevus	\$65,000	n/a	Tysabri	\$89,074	38.1%
Tecfidera	\$100,690	59.9%	Gilenya	\$105,390	58.2%
Copaxone	\$75K - \$86K	16.5%	Aubagio	\$93,296	40.9%

- Only 11% of those **with MS** said they could easily afford their DMT without financial assistance
- **More than half** are very concerned about how they will afford their medication in the future
- **85%** think the federal government should do more to control the high cost of MS medications

How have you altered use of an MS DMT?



With the rising cost of DMTs, **40% of those living with MS** are not able to stick to their treatment plan as prescribed by their provider. And **more than 1 in 10** of those surveyed stopped use of their DMT entirely, which opens the door to progression of MS.